Logo

Epidauros and InPheno to Co-Market Their PGx Services

Dec 01, 2006
NEW YORK (GenomeWeb News) — Epidauros and InPheno earlier this week said they plan to co-market their pharmacogenomic and phenotypic services to drug developers as a single service.
 
“We are trying to bring both genotype and phenotype analysis together because genetic analysis alone is not sufficient to predict statistical variance in clinical outcomes,” Hans Peter Arnold, director of business development and marketing at Epidauros, told GenomeWeb News this week.
 
The partnership could begin with marketing HIV services. InPheno already has an HIV analysis service, and Arnold said Epidauros expects to expand in that direction.
 
Epidauros CEO Michael Lutz said that adding InPheno’s capabilities in virology, oncology, and other diseases counts as an “important expansion” of the company’s clinical genotyping services.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.